Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07807722 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC

StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Exploring the efficacy and safety of firmonertinib combined with anlotinib and platinum-based doublet chemotherapy as neoadjuvant therapy in patients with EGFR-mutant resectable NSCLC
Trial Details
NCT Number NCT07807722
Lead Sponsor Hubei Cancer Hospital
Conditions
(from sponsor)		 NSCLC (Non-small Cell Lung Cancer), EGFR, Neoadjuvant Therapy
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov